- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Generic drug prices spike, but PBMs' reimbursement rates don't keep up, NCPA study finds
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- Study from NCPA sheds new light on med synchronization programs
- Roxane Labs' generic prostate drug gets tentative approval from FDA
COLUMBUS, Ohio Roxane Labs announced Thursday the launch of two new generic drugs.
The Columbus, Ohio-based generics subsidiary of German drug maker Boehringer Ingelheim, launched naratriptan tablets in the 1-mg and 2.5-mg strengths, and anastrozole tablets in the 1-mg strength.
Naratriptan tablets are used to treat acute migraine and are a generic version of GlaxoSmithKline’s Amerge, which had annual sales of around $60.2 million, according to IMS Health. Anastrozole is used to treat postmenopausal women with breast cancer and is a generic version of AstraZeneca’s Arimidex, which had annual sales of around $916.8 million.